Reducing the Risk of Diagnostic Error in the COVID-19 Era

Tejal K Gandhi, MD, MPH1, and Hardeep Singh, MD, MPH2*

1Press Ganey Associates LLC, Boston, Massachusetts; 2Center for Innovations in Quality, Effectiveness and Safety, Michael E. DeBakey Veterans Affairs Medical Center and Baylor College of Medicine, Houston, Texas.

A
s the death toll from the coronavirus disease 2019 (COVID-19) pandemic rapidly increases, the need to make a timely and accurate diagnosis has never been greater. Even before the pandemic, diagnostic errors (ie, missed, delayed, and incorrect diagnoses) had been one of the leading contributors to harm in health care.1 The COVID-19 pandemic is likely to increase the risk of such errors for several reasons. The disease itself is new and knowledge of its clinical manifestations is still evolving. Both physical and psychological safety of clinicians and health system capacity are compromised and can affect clinical decision-making.2 Situational factors such as staffing shortages and workarounds are more common, and clinicians in certain geographic areas are experiencing epic levels of stress, fatigue, and burnout. Finally, decisions in busy, chaotic and time-pressured healthcare systems with disrupted and/or newly designed care processes will be error prone.1

Based on emerging literature and collaborative discussions across the globe, we propose a new typology of diagnostic errors of concern in the COVID-19 era (Table). These errors span the entire continuum of care and have both systems-based and cognitive origins. While some errors arise from previously described clinical reasoning fallacies, others are unique to the pandemic. We provide a user-friendly nomenclature while describing eight types of diagnostic errors and highlight mitigation strategies to reduce potential preventable harm caused by those errors.

TYPES OF ANTICIPATED DIAGNOSTIC ERRORS

The classic COVID-19 presentation of a febrile respiratory illness warrants confirmatory testing, but testing may not be available or produce a false-negative result, leading to an error we termed “Classic.” In the United States, efforts to develop and implement testing protocols are still evolving. There is wide local and regional variation in type and availability of tests, as well as accessibility of information regarding test performance characteristics or diagnostic yield.3 Test results that are false negatives or testing that is not performed can lead to delayed diagnosis of the disease, as well as continued spread.

Testing is similarly relevant when patients present with unusual or nonrespiratory symptoms. Both predominantly olfactory and gastrointestinal manifestations have now been described, and mysterious new associations, such as multisystem inflammatory syndromes, continue to emerge. A failure to recognize atypical presentations and associations, either because of testing problems or knowledge gaps, could lead to overlooking underlying COVID-19 diagnosis, an error we termed “Anomalous.”

Another error emerging in the pandemic is mislabeling patients who do not have COVID-19 as having the disease, particularly those with respiratory symptoms. This usually occurs in absence of testing in an overwhelmed health system with limited capacity to test or treat (eg, clinicians just assume it must be COVID-19 when the test is not available). This type of labeling error, called “Anchor,” introduces the risk of missing other respiratory infections such as bacterial sinusitis and pneumonia, as well as nonrespiratory conditions.

In patients with known COVID-19, a second underlying or concurrent condition may be missed, an error we termed “Secondary.” For instance, reports of coagulopathy-related pulmonary embolism4 and strokes in young patients with minimal symptoms5 have emerged just recently. Respiratory compromise may be mistakenly attributed to COVID-19 rather than looking for a new source of worsening, such as pulmonary embolism. Similarly, clinicians may not recognize subtle stroke symptoms in patients who were otherwise feeling well at home. Such cognitive errors will likely increase as it becomes harder for clinicians or health systems to keep up with new knowledge.

Collateral effects of the COVID-19 pandemic are also emerging. For instance, patients with symptoms of new acute conditions may be unwilling to visit acute care for evaluation because of infection risk, an error we termed “Acute Collateral.” Concerns are already being raised that patients with acute myocardial infarction6 and stroke7 are not coming in for evaluation. Similarly, there may be delays in diagnosis of important ambulatory conditions, including cancer,8 when appointments or elective procedures are canceled (“Chronic Collateral”). In the United Kingdom, referrals under the 2-week wait system—in which suspected cancer patients referred by general practitioners are seen within 2-weeks—fell by 70% over March to April, 2020.

Diagnosis of non–COVID-19 patients coming into the hospital may also be affected because of the understandably heightened state of attention to COVID-19 patients, capacity, and staffing issues, an error we termed “Strain.” Physicians, including surgeons, pediatricians, and radiologists, have been “deployed” into acute care medical specialties. Cognitive errors increase when clinicians in new roles face unfamiliar sit-
TABLE. User-Friendly Nomenclature of Diagnostic Errors Anticipated in the COVID-19 Pandemic

<table>
<thead>
<tr>
<th>Nomenclature</th>
<th>Description</th>
<th>Additional Context</th>
</tr>
</thead>
<tbody>
<tr>
<td>Classic</td>
<td>Missed or delayed COVID-19 diagnosis in a patient who presents with respiratory symptoms</td>
<td>Currently the most well-known and common error mostly because of nonavailability of tests and/or false-negative tests.</td>
</tr>
<tr>
<td>Anomalous</td>
<td>Missed or delayed COVID-19 diagnosis in a patient who presents with nonrespiratory symptoms</td>
<td>Atypical symptoms including gastrointestinal symptoms (abdominal pain, diarrhea) and olfactory symptoms (anosmia) make it easier to miss the diagnosis, especially if respiratory symptoms are absent. New syndrome associations are emerging.</td>
</tr>
<tr>
<td>Anchor</td>
<td>Missed or delayed non–COVID-19 diagnosis because it was assumed to be COVID–19</td>
<td>Patients are being told they are “presumed COVID-19 positive,” which may or may not be true. Several conditions, including bacterial pneumonia, bronchitis, and sinusitis could be missed in absence of full evaluation including reliable and accurate testing.</td>
</tr>
<tr>
<td>Secondary</td>
<td>Missed or delayed non–COVID-19 or secondary diagnosis in a patient being treated with known COVID–19 disease</td>
<td>COVID–19 patients have coagulopathy and reports of concurrent pulmonary embolism have emerged. Worsening respiratory function may be attributed to the known COVID–19 diagnosis rather than a new pulmonary embolus. Concomitant infections (eg, influenza) can also be missed by attributing new symptoms to COVID–19.</td>
</tr>
<tr>
<td>Acute Collateral</td>
<td>Delayed diagnosis of acute non–COVID–19 diagnoses because patients are not coming in for evaluation due to infection risk</td>
<td>Recent concerns have been raised regarding reductions in admission for AMI and stroke because people may be staying home from fears of possible infection risk related to a trip to the hospital.</td>
</tr>
<tr>
<td>Chronic Collateral</td>
<td>Delayed diagnosis of ambulatory conditions when appointments or elective procedures are canceled</td>
<td>Examples include when a woman decides to cancel a screening mammogram that would have shown a worrisome finding or when the health system cancels a diagnostic colonoscopy that would have shown a malignancy.</td>
</tr>
<tr>
<td>Strain</td>
<td>Missed or delayed non–COVID–19 diagnosis in non–COVID–19 patient because of heightened state of attention to other COVID–19 patients in an overwhelmed health system</td>
<td>While hospitals are surging with COVID–19 patients, patients without COVID–19 may not get the same quality or timeliness of evaluation. Overcrowding and “hallway evaluation” is a known risk factor for disrupting the patient–clinician interaction and is associated with delays in care and failure to diagnose. Non–COVID–19 patients may get care from clinicians who are filling in for others and are possibly less experienced in the relevant domain of care.</td>
</tr>
<tr>
<td>Unintended</td>
<td>Any missed or delayed diagnosis because of less direct interactions, including rapid increase of telemedicine and PPE</td>
<td>Increasing use of telemedicine has been very beneficial but could be accompanied by certain risks as well, particularly of misdiagnosis. For example, a rash or abdominal pain could be misdiagnosed when only observed on a computer or phone screen rather than in-person or when there are technical difficulties with the connection.</td>
</tr>
</tbody>
</table>

Note: Error types may not be mutually exclusive.
Abbreviations: AMI, acute myocardial infarction; COVID–19, coronavirus disease of 2019; PPE, personal protective equipment.

utions and disease manifestations. Although these clinicians may be highly experienced previously, they may have insufficient skills and experience in their new roles and may not feel comfortable asking for guidance.11

Lastly, clinicians are increasingly using intermediary mechanisms, such as PPE and telemedicine technologies, to interact with patients. This is new for both parties and could introduce new types of errors, which we termed “Unintended.” Furthermore, interactions mediated via telemedicine technologies or PPE, as well as PPE conservation measures such as reduced room entries and e-consultation, may reduce the ability of even well-trained clinicians to take effective histories, perform physical exams, and monitor symptoms. In fact, infection-prevention isolation has been shown to put patients at risk of preventable adverse events in hospitalized patients.12

SPECIFIC MITIGATION STRATEGIES

There are many strategies that health systems could deploy to try to minimize these eight types of diagnostic errors. We organize mitigation strategies using the Safer Dx framework, which proposes sociotechnical approaches (ie, both technology and other systems-based approaches) to reduce diagnostic error.13

Technology for Cognitive Support

Up-to-date electronic decision support is needed to optimize test interpretation. Technology can also help scale and facilitate rapid adoption of standardized safety practices and protocols to address emerging risks areas. For instance, there are early efforts to create, implement, and disseminate smart algorithms to predict risks of non–COVID–19 diagnoses such as venous thromboembolism, patient transfer protocols on how best to reduce the burden at overstressed hospitals, protocols to triage rescheduling of elective procedures based on potential risk as determined from data in the electronic health record, new rules for creating outreach to patients who have missed appointments to prevent delays in their evaluation and diagnosis, and triage protocols and follow-up systems to optimize telemedicine.14

Optimized Workflow and Communication

When in-person contact is limited, specific practices (eg, providing patients with iPads, use of reflective listening, and use of optimal nonverbal communication strategies such as eye-contact) can still facilitate comprehensive discussions with patients and families about symptoms and encourage them to speak up if and when they have concerns.15 For patients reached through telemedicine, follow-up appointments and surveys should be done to ensure that symptoms and concerns have been addressed. For clinicians working in new clinical areas unfamiliar to them (eg, surgeons on medical floors, hospitalists
in ICUs), buddy systems can pair these clinicians with more experienced clinicians to make it easier for them to ask for help. Visual aids, decision support, and reliable error-prevention resources can also be helpful.16

People-Focused Interventions
Some clinicians are used to practicing solo, but this is the time to start “diagnostic huddles” for discussion of challenging cases with symptoms that are unusual or not improving as expected or for determining whether anything has been missed. In addition to encouraging patients to use reliable digital tools for self-triage, outreach to patients and the public must also advise them (with the help of public health authorities and the media) to seek medical assistance for certain important conditions such as acute myocardial infarction and stroke.

Organizational Strategies
Fundamental safety strategies must be ensured. First, it is critical to have a strong safety culture in which staff feel empowered to speak up, ask questions or ask for help, and report concerns without fear of repercussions or judgement. Culture can take years to develop, but due to rapidly changing circumstances in a crisis, there are ways for healthcare leaders to create changes more quickly. In addition to having daily huddles, leaders should be visible and communicate clearly about the behaviors and norms they are supporting. In particular, frequent leadership rounding (either virtually or in person)—during which leaders ask questions and encourage discussions of concerns in a supportive way—can foster the kind of culture that is needed. All organizations should implement peer support, counseling, limits on hours worked, and other support strategies for all clinicians to minimize the fatigue, stress, and anxiety that can impair cognitive function.17

Organizations must also be able to identify these errors to help understand root causes and prioritize interventions.18 For example, streamlined reporting systems that use apps and hotlines could be developed quickly to ensure that clinicians and patients/families can easily report these errors. Electronic triggers can help detect specific situations indicative of error or delay (eg, patient not on precautions gets switched to precautions during a hospitalization; absence of follow-up on abnormal tests).19

Learning systems—both within and across hospitals—should continue to share diagnostic challenges, the most up-to-date information, and best practices/protocols, and identify opportunities for improvement together. Many hospitals are having virtual grand rounds, journals are rapidly sharing new information via open access, regional and national cross-organizational and multidisciplinary learning networks of various groups have emerged (such as networks of oncologists, infectious disease specialists, and hospitalists), and new and transparent communication channels have developed between state and local health departments, government leaders, health systems, and the public. These forums should discuss emerging knowledge on diagnosis and strategies for risk reduction, many of which will unfold over the next few months.

State/Federal Policies and Regulations
While there is progress, additional challenges with accessibility, accuracy and performance of testing should be addressed at a national level. Guidance is needed on which asymptomatic people should be tested, both within and outside hospitals. Standardized metrics should be developed to monitor diagnostic performance and outcomes and evaluate how COVID-19 diagnosis errors affect different demographics. For instance, black and Hispanic individuals are disproportionately represented in COVID-19 cases and deaths, so metrics could be further stratified by race and ethnicity to ensure that we can understand and eliminate inequities, such as lack of access to care or testing.20

CONCLUSION
Clinicians must be provided with both cognitive and system support so they can do what they do best—diagnose and treat patients and save lives. Intermittent epidemic spikes based on location and season, including a potentially bigger spike of cases later this year, are now projected. Risks and recommendations discussed herein should therefore be rapidly shared to help redesign and strengthen the work system and protect patients from preventable diagnosis-related harm.

Disclosure: Dr Gandhi is an employee of Press Ganey Associates LLC. Dr Singh reported having nothing to disclose relevant to the published work.

Funding: Dr Singh is funded in part by the Houston Veterans Administration (VA) Health Services Research and Development (HSR&D) Center for Innovations in Quality, Effectiveness, and Safety (CIN13-413), the VA HSR&D Service (CRE17-127) and the Presidential Early Career Award for Scientists and Engineers USA 14-274, the VA National Center for Patient Safety, the Agency for Healthcare Research and Quality (R01HS27363), the CanTest Research Collaborative funded by a Cancer Research UK Population Research Catalyst award (C8640/A23385) and the Gordon and Betty Moore Foundation.

Disclaimer: The views expressed in this article do not represent the views of the U.S. Department of Veterans Affairs or the United States government.

References


